Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity
2025 · Lung Cancer · 1 citations
https://doi.org/10.1016/j.lungcan.2025.108799